News Column

Findings from I. Hofig and Colleagues Update Understanding of Lymphoma

May 26, 2014



By a News Reporter-Staff News Editor at Cancer Gene Therapy Week -- Investigators publish new report on Lymphoproliferative Disorders. According to news reporting from Martinsried, Germany, by NewsRx journalists, research stated, "Lentiviral vectors (LV) are widely used to successfully transduce cells for research and clinical applications. Lentiviral vectors pseudotyped with the vesicular stomatitis virus glycoprotein (VSV-G) can be produced to high titers and mediate high transduction efficiencies in vitro."

The news correspondents obtained a quote from the research, "For clinical applications the need for optimized transduction protocols and the limited activity of retronectin as LV enhancer, results in the application of a high multiplicity of infection (MOI) to achieve effective transduction efficiencies for a number of therapeutically relevant cells, e.g. CD34(+) hematopoietic stem cells, T- and B-cells. Our study describes an optimized LV infection protocol including a non-toxic poloxamer-based adjuvant combined with antibody-retargeted lentiviral particles, improving transduction efficiency at low MOI. Cell specificity of lentiviral vectors was increased by displaying different ratios of scFv-fused VSV-G glycoproteins on the viral envelope. The system was validated with difficult to transduce human CD30(+) lymphoma cells, and EGFR tumor cells. Highly efficient transduction of lymphoma cells was achieved, >50% of cells were transduced when MOI 1 was used. The scFv displaying lentiviral particles gained relative specificity for transduction of target cells. Preferential gene delivery to CD30(+) or EOM+ cells was increased 4-fold in mixed cell cultures by presenting scFv antibody fragments binding to respective surface markers."

According to the news reporters, the research concluded: "A combination of spinoculation, poloxamer-based chemical adjuvant, and LV displaying scFv fragments increases transduction efficiencies of hard-to-transduce suspension lymphoma cells, and promises new chances for the future development of improved clinical protocols."

For more information on this research see: Systematic improvement of lentivirus transduction protocols by antibody fragments fused to VSV-G as envelope glycoprotein. Biomaterials, 2014;35(13):4204-4212. Biomaterials can be contacted at: Elsevier Sci Ltd, The Boulevard, Langford Lane, Kidlington, Oxford OX5 1GB, Oxon, England. (Elsevier - www.elsevier.com; Biomaterials - www.elsevier.com/wps/product/cws_home/30392)

Our news journalists report that additional information may be obtained by contacting I. Hofig, Sirion Biotech GmbH, D-82152 Martinsried, Germany. Additional authors for this research include S. Barth, M. Salomon, V. Jagusch, M.J. Atkinson, N. Anastasov and C. Thirion (see also Lymphoproliferative Disorders).

Keywords for this news article include: Antibodies, Biotechnology, Europe, Germany, Oncology, Hematology, Immunology, Martinsried, Therapeutics, Glycoproteins, Bioengineering, Blood Proteins, Glycoconjugates, Immunoglobulins, Lymphatic Diseases, Lymphoma Gene Therapy, Immunoproliferative Disorders, Lymphoproliferative Disorders

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Cancer Gene Therapy Week


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters